clinical trial · NCT06057571
Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor
TransThera Sciences (Nanjing), Inc.·phase2·active not recruiting·n = 50
Cholangiocarcinoma MetastaticTT-00420 (tinengotinib)
brief summary
A phase II, open-label, multicenter study to evaluate the efficacy and safety of oral TT-00420 (Tinengotinib) tablets in subjects with cholangiocarcinoma who failed or relapsed to prior treatment of chemotherapy and FGFR Inhibitor.
started
Nov 17, 2023
primary completion
Jul 27, 2025
completion
Dec 31, 2025
last updated
Aug 21, 2025
detailed description
Approximately 50 subjects will be enrolled. Eligible subjects will receive tinengotinib 10 mg QD orally as the initial dose level in 21-day cycles until confirmed disease progression, intolerable toxicity, death, or withdrawal of consent.
official title
A Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Oral TT-00420 (Tinengotinib) Tablets in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Prior Treatment of Chemotherapy and FGFR Inhibitor
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol